Volume 30, Number 6—June 2024
Dispatch
Invasive Pulmonary Aspergillosis in Critically Ill Patients with Hantavirus Infection, Austria
Table 2
Characteristic | Patient 1, DOBV infection | Patient 2, PUUV infection |
---|---|---|
EORTC risk factors | None | None |
APACHE II score | 36 | 26 |
Thoracic CT scan/radiograph | Bilateral dense infiltrates | Bilateral dense infiltrates |
Steroids to treat pneumonia | Yes | Yes |
Renal replacement therapy | Yes | Yes |
Vasopressor | High-dose nordarenalin and vasopressin | High-dose nordarenalin and vasopressin |
BAL Aspergillus culture | + | + |
BAL Aspergillus qPCR | − | − |
BAL galactomannan index | 7,11 | 7,71 |
Serum Aspergillus qPCR | NA | NA |
β-D-glucan, pg/mL | 126 | 626 |
Serum galactomannan index | 0.79 | 0.32 |
Mycologic criteria | 4 | 3 |
Antifungal therapy | Voriconazole | Posaconazole |
Outcome | Dead | Alive |
*The table summarizes diagnostic and therapeutic characteristics of invasive pulmonary aspergillosis associated with hantavirus-disease. APACHE score, Acute Physiology and Chronic Health Evaluation score; BAL, bronchoalveolar lavage; CT, computed tomography; EORTC, European Organisation for Research and Treatment of Cancer; NA, not available; qPCR, quantitative PCR; +, positive; −, negative.
Page created: May 09, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.